A Study to Evaluate the Safety, PK/PD of OriCAR-017 in Subjects With RR/MM - RIGEL Study
Phase 1
81
about 4 years
18–75
1 site in GA
About this study
Researchers are testing a treatment called OriCAR-017 for people with relapsed or refractory multiple myeloma. The trial will evaluate how safe and effective this treatment is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take OriCAR-017
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD) of OriCAR-017 US-P1
Secondary: Assessment of Disease Control Rate (DCR), Assessment of Duration of Response (DOR) of treatment in patients with RR/MM, Assessment of Overall Response Rate (ORR), Assessment of Overall Survival (OS) of treatment in patients with RR/MM, Evaluate PD parameters of OriCAR-017 in subjects with relapsed/refractory MM, Evaluate PK parameters of OriCAR-017 in subjects with relapsed/refractory MM, Progress-Free Survival (PFS) of treatment in patients with RR/MM
Cardiology / Heart, Oncology